Strategies for Tuning the Selectivity of Chemical Probes That Target Serine Hydrolases
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Bran Serine Hydrolases Achintya Kumar Dolui1,2, Arun Kumar Vijayakumar2,3, Ram Rajasekharan1,2,4 & Panneerselvam Vijayaraj1,2*
www.nature.com/scientificreports OPEN Activity‑based protein profling of rice (Oryza sativa L.) bran serine hydrolases Achintya Kumar Dolui1,2, Arun Kumar Vijayakumar2,3, Ram Rajasekharan1,2,4 & Panneerselvam Vijayaraj1,2* Rice bran is an underutilized agricultural by‑product with economic importance. The unique phytochemicals and fatty acid compositions of bran have been targeted for nutraceutical development. The endogenous lipases and hydrolases are responsible for the rapid deterioration of rice bran. Hence, we attempted to provide the frst comprehensive profling of active serine hydrolases (SHs) present in rice bran proteome by activity‑based protein profling (ABPP) strategy. The active site‑directed fuorophosphonate probe (rhodamine and biotin‑conjugated) was used for the detection and identifcation of active SHs. ABPP revealed 55 uncharacterized active‑SHs and are representing fve diferent known enzyme families. Based on motif and domain analyses, one of the uncharacterized and miss annotated SHs (Os12Ssp, storage protein) was selected for biochemical characterization by overexpressing in yeast. The purifed recombinant protein authenticated the serine protease activity in time and protein‑dependent studies. Os12Ssp exhibited the maximum activity at a pH between 7.0 and 8.0. The protease activity was inhibited by the covalent serine protease inhibitor, which suggests that the ABPP approach is indeed reliable than the sequence‑based annotations. Collectively, the comprehensive knowledge generated from this study would be useful in expanding the current understanding of rice bran SHs and paves the way for better utilization/ stabilization of rice bran. Rice (Oryza sativa) is one of the major staple foods for almost half the world’s population, especially in Asia 1. -
) (51) International Patent Classification: Columbia V5G 1G3
) ( (51) International Patent Classification: Columbia V5G 1G3 (CA). PANDEY, Nihar R.; 10209 A 61K 31/4525 (2006.01) C07C 39/23 (2006.01) 128A St, Surrey, British Columbia V3T 3E7 (CA). A61K 31/05 (2006.01) C07D 405/06 (2006.01) (74) Agent: ZIESCHE, Sonia et al.; Gowling WLG (Canada) A61P25/22 (2006.01) LLP, 2300 - 550 Burrard Street, Vancouver, British Colum¬ (21) International Application Number: bia V6C 2B5 (CA). PCT/CA2020/050165 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection av ailable) . AE, AG, AL, AM, 07 February 2020 (07.02.2020) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 16/270,389 07 February 2019 (07.02.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (63) Related by continuation (CON) or continuation-in-part SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (CIP) to earlier application: TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. US 16/270,389 (CON) (84) Designated States (unless otherwise indicated, for every Filed on 07 Februaiy 2019 (07.02.2019) kind of regional protection available) . -
An ER Stress/Defective Unfolded Protein Response Model Richard T
ORIGINAL RESEARCH Ethanol Induced Disordering of Pancreatic Acinar Cell Endoplasmic Reticulum: An ER Stress/Defective Unfolded Protein Response Model Richard T. Waldron,1,2 Hsin-Yuan Su,1 Honit Piplani,1 Joseph Capri,3 Whitaker Cohn,3 Julian P. Whitelegge,3 Kym F. Faull,3 Sugunadevi Sakkiah,1 Ravinder Abrol,1 Wei Yang,1 Bo Zhou,1 Michael R. Freeman,1,2 Stephen J. Pandol,1,2 and Aurelia Lugea1,2 1Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California; 2Department of Medicine, or 3Psychiatry and Biobehavioral Sciences, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California Pancreatic acinar cells Pancreatic acinar cells - no pathology - - Pathology - Ethanol feeding ER sXBP1 Pdi, Grp78… (adaptive UPR) aggregates Proper folding and secretion • disordered ER of proteins processed in the • impaired redox folding endoplasmic reticulum (ER) • ER protein aggregation • secretory defects SUMMARY METHODS: Wild-type and Xbp1þ/- mice were fed control and ethanol diets, then tissues were homogenized and fraction- Heavy alcohol consumption is associated with pancreas ated. ER proteins were labeled with a cysteine-reactive probe, damage, but light drinking shows the opposite effects, isotope-coded affinity tag to obtain a novel pancreatic redox ER reinforcing proteostasis through the unfolded protein proteome. Specific labeling of active serine hydrolases in ER with response orchestrated by X-box binding protein 1. Here, fluorophosphonate desthiobiotin also was characterized pro- ethanol-induced changes in endoplasmic reticulum protein teomically. Protein structural perturbation by redox changes redox and structure/function emerge from an unfolded was evaluated further in molecular dynamic simulations. protein response–deficient genetic model. -
Catalysis by Acetylcholinesterase
Proc. Nat. Acad. Sci. USA Vol. 72, No. 10, pp. 3834-38, October 1975 Biochemistry Catalysis by acetylcholinesterase: Evidence that the rate-limiting step for acylation with certain substrates precedes general acid-base catalysis (enzyme mechanism/diffusion control/induced-fit conformational change/pH dependence/deuterium oxide isotope effects) TERRONE L. ROSENBERRY Departments of Biochemistry and Neurology, College of Physicians and Surgeons, Columbia University, New York, N.Y. 10032 Communicated by David Nachmansohn, June 9,1975 ABSTRACT Inferences about the catalytic mechanism of The proposed intermediates include the initial Michaelis acetylcholinesterase (acetyicholine hydrolase, EC 3.1.1.7) are complex E-RX and the acyl enzyme ER, for which evidence frequently made on the basis of a presumed analogy with has long been obtained (5, 6, 1). The pH dependence of sub- chymotrypsin, EC 3.4.21.1. Although both enzymes are serine hydrolases, several differences in the steady-state kinetic strate hydrolysis for chymotrypsin and other serine hydro- properties of the two have been observed. In this report par- lases suggests general acid-base catalysis by a group in the ticujar attention is focused on the second-order reaction con- free enzyme with a pKai of 6 to 7. Furthermore, Hammett stant, kcat/KapD While the reported pH dependence and deu- relationships with positive rho values are found with chymo- terium oxide isotope effect associated with this parameter trypsin both for deacylation (7) and acylation (8) reactions for chymotrypsin are generally consistent with simple mod- and indicate rate-limiting general base catalysis. Deacyla- els involving rate-limiting general acid-base catalysis, this study finds a more complicated situation with acetylcholi- tion rates are typically reduced in deuterium oxide by fac- nesterase. -
TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. -
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z
REVIEW pubs.acs.org/CR The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z. Long* and Benjamin F. Cravatt* The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States CONTENTS 2.4. Other Phospholipases 6034 1. Introduction 6023 2.4.1. LIPG (Endothelial Lipase) 6034 2. Small-Molecule Hydrolases 6023 2.4.2. PLA1A (Phosphatidylserine-Specific 2.1. Intracellular Neutral Lipases 6023 PLA1) 6035 2.1.1. LIPE (Hormone-Sensitive Lipase) 6024 2.4.3. LIPH and LIPI (Phosphatidic Acid-Specific 2.1.2. PNPLA2 (Adipose Triglyceride Lipase) 6024 PLA1R and β) 6035 2.1.3. MGLL (Monoacylglycerol Lipase) 6025 2.4.4. PLB1 (Phospholipase B) 6035 2.1.4. DAGLA and DAGLB (Diacylglycerol Lipase 2.4.5. DDHD1 and DDHD2 (DDHD Domain R and β) 6026 Containing 1 and 2) 6035 2.1.5. CES3 (Carboxylesterase 3) 6026 2.4.6. ABHD4 (Alpha/Beta Hydrolase Domain 2.1.6. AADACL1 (Arylacetamide Deacetylase-like 1) 6026 Containing 4) 6036 2.1.7. ABHD6 (Alpha/Beta Hydrolase Domain 2.5. Small-Molecule Amidases 6036 Containing 6) 6027 2.5.1. FAAH and FAAH2 (Fatty Acid Amide 2.1.8. ABHD12 (Alpha/Beta Hydrolase Domain Hydrolase and FAAH2) 6036 Containing 12) 6027 2.5.2. AFMID (Arylformamidase) 6037 2.2. Extracellular Neutral Lipases 6027 2.6. Acyl-CoA Hydrolases 6037 2.2.1. PNLIP (Pancreatic Lipase) 6028 2.6.1. FASN (Fatty Acid Synthase) 6037 2.2.2. PNLIPRP1 and PNLIPR2 (Pancreatic 2.6.2. -
Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators S
Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/10/10/jpet.118.252296.DC1 1521-0103/367/3/494–508$35.00 https://doi.org/10.1124/jpet.118.252296 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 367:494–508, December 2018 Copyright ª 2018 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators s Jason R. Clapper, Cassandra L. Henry, Micah J. Niphakis, Anna M. Knize, Aundrea R. Coppola, Gabriel M. Simon, Nhi Ngo, Rachel A. Herbst, Dylan M. Herbst, Alex W. Reed, Justin S. Cisar, Olivia D. Weber, Andreu Viader, Jessica P. Alexander, Mark L. Cunningham, Todd K. Jones, Iain P. Fraser, Cheryl A. Grice, R. Alan B. Ezekowitz, ’ Gary P. O Neill, and Jacqueline L. Blankman Downloaded from Abide Therapeutics, San Diego, California Received July 26, 2018; accepted October 5, 2018 ABSTRACT Monoacylglycerol lipase (MGLL) is the primary degradative whether selective MGLL inhibition would affect prostanoid pro- jpet.aspetjournals.org enzyme for the endocannabinoid 2-arachidonoylglycerol (2- duction in several human assays known to be sensitive AG). The first MGLL inhibitors have recently entered clinical to cyclooxygenase inhibitors. ABD-1970 robustly elevated brain development for the treatment of neurologic disorders. To 2-AG content and displayed antinociceptive and antipru- support this clinical path, we report the pharmacological ritic activity in a battery of rodent models (ED50 values of characterization of the highly potent and selective MGLL inhibitor 1–2 mg/kg). -
Sox2 Promotes Malignancy in Glioblastoma by Regulating
Volume 16 Number 3 March 2014 pp. 193–206.e25 193 www.neoplasia.com Artem D. Berezovsky*, Laila M. Poisson†, Sox2 Promotes Malignancy in ‡ ‡ David Cherba , Craig P. Webb , Glioblastoma by Regulating Andrea D. Transou*, Nancy W. Lemke*, Xin Hong*, Laura A. Hasselbach*, Susan M. Irtenkauf*, Plasticity and Astrocytic Tom Mikkelsen*,§ and Ana C. deCarvalho* Differentiation1,2 *Department of Neurosurgery, Henry Ford Hospital, Detroit, MI; †Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI; ‡Program of Translational Medicine, Van Andel Research Institute, Grand Rapids, MI; §Department of Neurology, Henry Ford Hospital, Detroit, MI Abstract The high-mobility group–box transcription factor sex-determining region Y–box 2 (Sox2) is essential for the maintenance of stem cells from early development to adult tissues. Sox2 can reprogram differentiated cells into pluripotent cells in concert with other factors and is overexpressed in various cancers. In glioblastoma (GBM), Sox2 is a marker of cancer stemlike cells (CSCs) in neurosphere cultures and is associated with the proneural molecular subtype. Here, we report that Sox2 expression pattern in GBM tumors and patient-derived mouse xenografts is not restricted to a small percentage of cells and is coexpressed with various lineage markers, suggesting that its expression extends beyond CSCs to encompass more differentiated neoplastic cells across molecular subtypes. Employing a CSC derived from a patient with GBM and isogenic differentiated cell model, we show that Sox2 knockdown in the differentiated state abolished dedifferentiation and acquisition of CSC phenotype. Furthermore, Sox2 deficiency specifically impaired the astrocytic component of a biphasic gliosarcoma xenograft model while allowing the formation of tumors with sarcomatous phenotype. -
Serine Hydrolases Involved in Lipid Metabolism in P
Article The Antimalarial Natural Product Salinipostin A Identifies Essential a/b Serine Hydrolases Involved in Lipid Metabolism in P. falciparum Parasites Graphical Abstract Authors Euna Yoo, Christopher J. Schulze, Barbara H. Stokes, ..., Eranthie Weerapana, David A. Fidock, Matthew Bogyo Correspondence [email protected] In Brief Using a probe analog of the antimalarial natural product Sal A, Yoo et al. identify its targets as multiple essential serine hydrolases, including a homolog of human monoacylglycerol lipase. Because parasites were unable to generate robust in vitro resistance to Sal A, these enzymes represent promising targets for antimalarial drugs. Highlights d Semi-synthesis of an affinity analog of the antimalarial natural product Sal A d Identification of serine hydrolases as the primary targets of Sal A in P. falciparum d Sal A covalently binds to and inhibits a MAGL-like protein in P. falciparum d Parasites are unable to generate strong in vitro resistance to Sal A Yoo et al., 2020, Cell Chemical Biology 27, 143–157 February 20, 2020 ª 2020 Elsevier Ltd. https://doi.org/10.1016/j.chembiol.2020.01.001 Cell Chemical Biology Article The Antimalarial Natural Product Salinipostin A Identifies Essential a/b Serine Hydrolases Involved in Lipid Metabolism in P. falciparum Parasites Euna Yoo,1,11 Christopher J. Schulze,1,11 Barbara H. Stokes,2 Ouma Onguka,1 Tomas Yeo,2 Sachel Mok,2 Nina F. Gnadig,€ 2 Yani Zhou,3 Kenji Kurita,4 Ian T. Foe,1 Stephanie M. Terrell,1,5 Michael J. Boucher,6,7 Piotr Cieplak,8 Krittikorn Kumpornsin,9 Marcus C.S. Lee,9 Roger G. -
The Molecular Biology of Pancreatic Adenocarcinoma: Translational Challenges and Clinical Perspectives
Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives Shun Wang1, Yan Zheng1, Feng Yang2, Le Zhu1, Xiao-Qiang Zhu3, Zhe-Fang Wang4, Xiao-Lin Wu4, Cheng-Hui Zhou4, Jia-Yan Yan4,5, Bei-Yuan Hu1, Bo Kong6, De-Liang Fu2, Christiane Bruns4, Yue Zhao4, Lun-Xiu Qin1 and Qiong-Zhu Dong 1,7 Pancreatic cancer is an increasingly common cause of cancer mortality with a tight correspondence between disease mortality and incidence. Furthermore, it is usually diagnosed at an advanced stage with a very dismal prognosis. Due to the high heterogeneity, metabolic reprogramming, and dense stromal environment associated with pancreatic cancer, patients benefit little from current conventional therapy. Recent insight into the biology and genetics of pancreatic cancer has supported its molecular classification, thus expanding clinical therapeutic options. In this review, we summarize how the biological features of pancreatic cancer and its metabolic reprogramming as well as the tumor microenvironment regulate its development and progression. We further discuss potential biomarkers for pancreatic cancer diagnosis, prediction, and surveillance based on novel liquid biopsies. We also outline recent advances in defining pancreatic cancer subtypes and subtype-specific therapeutic responses and current preclinical therapeutic models. Finally, we discuss prospects and challenges in the clinical development of pancreatic cancer therapeutics. -
Liquid Biopsy Biomarkers in Bladder Cancer: a Current Need for Patient Diagnosis and Monitoring
Review Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring Iris Lodewijk 1,2, Marta Dueñas 1,2,3, Carolina Rubio 1,2,3, Ester Munera-Maravilla 1,2, Cristina Segovia 1,2,3, Alejandra Bernardini 1,2,3, Alicia Teijeira 1, Jesús M. Paramio 1,2,3 and Cristian Suárez-Cabrera 1,2,* 1 Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Avenida Complutense nº 40, 28040 Madrid, Spain; [email protected] (I.L.); [email protected] (M.D.); [email protected] (C.R.); [email protected] (E.M.-M.); [email protected] (C.S.); [email protected] (A.B.); [email protected] (A.T.); [email protected] (J.M.P.) 2 Biomedical Research Institute I+12, University Hospital “12 de Octubre”, Av Córdoba s/n, 28041 Madrid, Spain 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-91-496-6438 Received: 28 July 2018; Accepted: 21 August 2018; Published: 24 August 2018 Abstract: Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance. -
The Dark Side of the Human Genome
TECHNOLOGY FEATURE THE DARK SIDE OF THE HUMAN GENOME Scientists are uncovering the hidden switches in our genome that dial gene expression up and down, but much work lies ahead to peel back the many layers of regulation. MEHAU KULYK/SPL MEHAU The human genome is not packed with ‘junk’ as previously thought, but with regulatory regions that modulate gene activity. BY KELLY RAE CHI expression in ways that scientists are only of non-coding portions, that drive when and starting to unravel. By uncovering regulatory where genes are expressed. Scientists have ifteen years ago, scientists celebrated instructions in the genome beyond protein- generated a list of such elements by using bio- the first draft of the sequenced human coding genes, scientists are hoping to yield chemical assays to probe DNA sequences, RNA genome. At the time, they predicted that new ways to understand and treat disease. “It’s transcripts, regulatory proteins bound to DNA Fhumans had between 25,000 and 40,000 genes not overstating to say that ENCODE is as sig- and RNA and epigenetic signatures — the chem- that code for proteins. That estimate has con- nificant for our understanding of the human ical tags on DNA and the proteins packaging it tinued to fall. Humans actually seem to have genome as the original DNA sequencing of the — that also affect gene expression. as few as 19,000 such genes1 — a mere 1–2% of human genome,” says cell biologist Bing Ren of So far, the data suggest that there are the genome. The key to our complexity lies in the University of California, San Diego, Insti- hundreds of thousands of functional regions how these genes are regulated by the remain- tute for Genomic Medicine in La Jolla, who is in the human genome whose task is to control ing 99% of our DNA, known as the genome’s a member of the ENCODE team.